Trading At Over Twice The 52 Week Low, Altimmune Inc (NYSE:ALT) Close At $13.90

Altimmune Inc (NYSE:ALT)

September 24th, 2018

Altimmune Inc fell $12.29 Monday which equals a 46.93% decline, closing at $13.90. While the stock did drop today, remember that it is still trading at 5,460% of its 52 week low of $0.25. Despite the drop in value, trading volumes were solid at 443% of normal which can indicate investor opportunities. Be aware that the Piotroski Score1 is calculated to be 2, which is very low as the scale goes from 0-9. This is considered to be a weak score in terms of financial strength.

ALT was outperformed by the rest of the Healthcare sector which went up 0.16%.

Market Sectors

The market sectors were mixed Monday with a majority of the sectors trending down. Energy saw the biggest increase of the day (1.47%), while Real Estate saw the biggest drop (1.89%). Consumer Discretionary has seen the biggest year-to-date gain at 19%. The biggest loss this year has been the Communication Services sector dropping 4.34%.

Information Technology saw the biggest turnaround from its 5-day performance of -0.06%, as it went up 0.31%. Consumer Staples and Materials saw turn arounds from their five day positive performance, Consumer Staples with a drop of 1.50%.

Sector Breakdown

  • Energy went up with a 1.47% change.
  • Information Technology went up with a 0.31% change.
  • Communication Services went up with a 0.21% change.
  • Healthcare went up with a 0.16% change.
  • Consumer Discretionary went down with a -0.57% change.
  • Utilities went down with a -0.89% change.
  • Financials went down with a -1.06% change.
  • Industrials went down with a -1.32% change.
  • Materials went down with a -1.41% change.
  • Consumer Staples went down with a -1.50% change.
  • Real Estate went down with a -1.89% change.

Altimmune Inc Info

As of May 4, 2017, PharmAthene, Inc. was acquired by Altimmune, Inc. in a reverse merger transaction. PharmAthene, Inc., a biodefense company, develops and commercializes medical countermeasures against biological and chemical threats in the United States. The company focuses on developing lyophilized anthrax vaccine based on its proprietary technology platform. It serves National Institute of Allergy and Infectious Diseases, and the Biomedical Advanced Research and Development Authority. PharmAthene, Inc. is headquartered in Annapolis, Maryland.

All amounts in USD unless otherwise indicated

(1) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Altimmune Inc’s score is ), and 9 is the best.

ALT daily update
ALT daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.